The Systems Biology of Drug Resistance in Cancer group, led by professor Sampsa Hautaniemi, focuses on understanding and finding effective means to overcome drug resistance in cancers. Our approach is to use systems biology, i.e., analyze molecular & clinical data from cancer patients with machine learning and mathematical methods, to identify efficient patient-specific therapeutic targets. Our work is cross-disciplinary and done in close collaboration with researchers from various disciplines, including clinicians, cell biologists and geneticians. The main objective of our research is to obtain hypotheses and predictions that can be tested in wet-lab or in clinical trials and thereby translate medical data into benefits in cancer patient care.
Read more
@HautaniemiLab

Very exciting new results on #AI methods to predict outcome in #ovariancancer published now! nature.com/articles/s4159…

We have posted an updated version of our preprint on interpreting pairwise dependencies learned by deep learning mo… twitter.com/i/web/status/1…

Innostaako monipuoliset työtehtävät kansainvälisessä akateemisessa ympäristössä? Hae viim. 19.9 ja tule projektikoo… twitter.com/i/web/status/1…

Kinase inhibitors are among the most successful drug classes ever - yet they have so much more to give, with 70% of… twitter.com/i/web/status/1…